Efficacy and safety of the proposed biosimilar PERT-IJS versus EU-Perjeta® along with trastuzumab and chemotherapy (carboplatin and docetaxel) as neoadjuvant treatment in chemotherapy naïve patients with early stage or locally advanced HR negative and HER2 positive breast cancer

2023-506163-34-00 Protocol BIO-PERTUZ-301 Therapeutic confirmatory (Phase III) Ended

End 24 Feb 2025 · Status Ended · 2 EU/EEA countries · 10 sites · Protocol BIO-PERTUZ-301

Overview

Sponsor-declared trial summary

Phase Therapeutic confirmatory (Phase III)
Status Ended
Participants planned 382
Countries 2
Sites 10

Hormone Receptor Negative (HR-ve) Human Epidermal Growth Factor Receptor 2 (HER2)-positive Early Stage or Locally Advanced Breast Cancer

Key facts

Sponsor
Biocon Biologics UK Limited
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
completed 24 Feb 2025
Decision date (initial)
2023-11-22
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Hormone Receptor Negative (HR-ve) Human Epidermal Growth Factor Receptor 2 (HER2)-positive Early Stage or Locally Advanced Breast Cancer

VersionLevelCodeTermSystem organ class
21.1 LLT 10072740 Locally advanced breast cancer 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Biocon Biologics UK Limited

Sponsor organisation
Biocon Biologics UK Limited
Address
16 Great Queen Street
City
London
Postcode
WC2B 5AH
Country
United Kingdom

Scientific contact point

Organisation
Biocon Biologics UK Limited
Contact name
Dr. Anoop Chullikana

Public contact point

Organisation
Biocon Biologics UK Limited
Contact name
Jayanti Panda

Locations

2 EU/EEA countries · 10 investigational sites

By country

CountryMS statusPlanned subjectsSites
Poland Ended 31 7
Romania Ended 15 3
Rest of world
Taiwan, Philippines, Georgia, India
336

Investigational sites

Poland

7 sites · Ended
Wojewodzki Szpital Specjalistyczny W Bialej Podlaskiej
Oddział Onkologii Klinicznej, Ul. Terebelska 57/65, 21-500, Biala Podlaska
Pratia S.A.
Pratia MCM Kraków, Ul. Pana Tadeusza 2, 30-727, Cracow
Szpital Specjalistyczny Im. Ludwika Rydygiera W Krakowie Sp. z o.o.
Onkologia Kliniczna, Os. Zlotej Jesieni 1, 31-826, Cracow
Instytut Msf Sp. z o.o.
N/A, Ul. Pilota Stanislawa Wigury 19, 90-302, Lodz
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy
Klinika Nowotworów Piersi i Chirurgii Rekonstrukcyjnej, Ul. Wilhelma Konrada Roentgena 5, 02-781, Warsaw
Centra Medyczne Medyceusz Sp. z o.o.
n/a, Ul. Bazarowa 9, 91-053, Lodz
Mruk-Med I Sp. z o.o.
Poradnia Onkologiczna, Ul. Gen. Mariana Langiewicza 61, 35-021, Rzeszow

Romania

3 sites · Ended
Centrul De Oncologie SF Nectarie S.R.L.
Oncology, Strada Caracal Nr 109, 200542, Craiova
Sigmedical Services S.R.L.
Oncology, Bis The Building Corp A, Strada Zamca Nr 21, Suceava
Spital Clinic Militar De Urgenta Dr. Constantin Papilian Cluj Napoca
Oncology & Chemotherapy, Strada General Traian Mosoiu No 22, 400132, Cluj-Napoca

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-07-28 Poland Acceptable with conditions
2023-11-20
2023-11-22